Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis

BACKGROUND: Infliximab, a chimeric, monoclonal, anti-TNF antibody has been shown to be safe and efficacious for refractory sarcoidosis, we investigated whether adalimumab, a fully human, anti-TNF monoclonal antibody, is similarly safe and efficacious in refractory pulmonary sarcoidosis. METHODS: An...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sweiss, Nadera J., Noth, Imre, Mirsaeidi, Mehdi, Zhang, Wei, Naureckas, Edward T., Hogarth, D. Kyle, Strek, Mary, Caligiuri, Philip, Machado, Roberto F, Niewold, Timothy B, Garcia, Joe G.N., Pangan, Aileen L., Baughman, Robert P.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4134103/
https://ncbi.nlm.nih.gov/pubmed/24751453
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars